Co-stimulation agonists as a new immunotherapy for autoimmune diseases

Yonglian Sun, Sumit K. Subudhi, Yang Xin Fu

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Lymphocytes are important in the pathogenesis of many autoimmune diseases. Blocking co-stimulatory signals for T-cell activation has been widely used as an approach to treating autoimmunity, but it has encountered limited clinical success. Some agonistic monoclonal antibodies to co-stimulatory molecules greatly enhance immune responses mediated by T cells, such as antiviral, anti-tumor and alloresponses. Surprisingly, recent studies have demonstrated that these agonists have profound therapeutic effects on autoimmune diseases by potentially depleting autoreactive lymphocytes or by inhibiting their function. These findings imply that signaling through co-stimulatory molecules can have diametric! outcomes in modulating immune responses, thereby providing a novel approach to the treatment of autoimmune diseases.

Original languageEnglish (US)
Pages (from-to)483-489
Number of pages7
JournalTrends in Molecular Medicine
Issue number11
StatePublished - Nov 2003

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology


Dive into the research topics of 'Co-stimulation agonists as a new immunotherapy for autoimmune diseases'. Together they form a unique fingerprint.

Cite this